ESMO: European Society for Medical Oncology

The latest news from ESMO
  1. New anticancer drugs substantially reduce the risk of death and tumour progression, but only marginally extend patient survival

  2. It is indicated for the first-line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%

  3. Findings from the single-arm, phase II study

  4. Findings from the TUXEDO-1 study

  5. Findings from the ARCAGEN study (EORTC-1843)